PGEN

MKT CAP:$1B

Precigen, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.96-$0.32 (-7.48%)

Apr 23, 2026

Company Details

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reprodu...

CEO

Helen Sabzevari

IPO Date

Aug 8, 2013

Website

www.precigen.com

Key Metrics TTM

Revenue

$10M

+146.7% YoY

Net Income

-$251M

EPS (Diluted)

-$1.44

Free Cash Flow

-$90M

Revenue / Share

$0.03

Gross Margin

42.1%

Operating Margin

-1141.1%

Net Margin

-2588.2%

FCF Margin

-933.8%

P/S

129.5x

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 25, 2026

$10M+146.7%EPS -$1.41

Q4 2025

Mar 25, 2026

$5M+283.6%EPS -$0.07

Q3 2025

Nov 13, 2025

$3M+206.6%EPS -$1.10

Q2 2025

Aug 12, 2025

$856.0K+19.4%EPS -$0.09

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$6M	-$8M	-$22M
Q2 22	$3M	$1M	-$24M
Q3 22	$17M	$3M	-$8M
Q4 22	$2M	$506.0K	-$22M
Q1 23	$2M	$324.0K	-$23M
Q2 23	$2M	$70.0K	-$21M
Q3 23	$1M	-$158.0K	-$21M
Q4 23	$1M	-$1M	-$23M
Q1 24	$1M	-$810.5K	-$24M
Q2 24	$717.0K	-$297.0K	-$61M
Q3 24	$953.0K	-$56.0K	-$21M
Q4 24	$1M	$21.0K	-$29M
Q1 25	$1M	$241.0K	-$23M
Q2 25	$856.0K	-$699.0K	-$32M
Q3 25	$3M	$2M	-$34M
Q4 25	$5M	$3M	-$22M

Valuation

Quarter	P/S	P/E
Q1 22	24.9x	—
Q2 22	18.0x	—
Q3 22	14.6x	16.5x
Q4 22	13.3x	12.7x
Q1 23	11.9x	11.2x
Q2 23	12.7x	12.7x
Q3 23	47.5x	—
Q4 23	56.0x	—
Q1 24	66.4x	—
Q2 24	97.4x	—
Q3 24	70.0x	—
Q4 24	69.6x	—
Q1 25	104.2x	—
Q2 25	96.2x	—
Q3 25	170.6x	—
Q4 25	136.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$19M	-$20M
Q2 22	-$7M	-$9M
Q3 22	-$24M	-$25M
Q4 22	-$15M	-$15M
Q1 23	-$18M	-$19M
Q2 23	-$16M	-$16M
Q3 23	-$17M	-$17M
Q4 23	-$16M	-$17M
Q1 24	-$14M	-$18M
Q2 24	-$23M	-$25M
Q3 24	-$23M	-$24M
Q4 24	-$8M	-$9M
Q1 25	-$16M	-$17M
Q2 25	-$19M	-$20M
Q3 25	-$29M	-$29M
Q4 25	-$23M	-$24M

Capital Expenditures

Quarter	CapEx
Q1 22	$2M
Q2 22	$2M
Q3 22	$2M
Q4 22	$53.0K
Q1 23	$154.0K
Q2 23	$101.0K
Q3 23	$236.0K
Q4 23	$1M
Q1 24	$4M
Q2 24	$2M
Q3 24	$882.0K
Q4 24	$1M
Q1 25	$622.0K
Q2 25	$966.0K
Q3 25	$389.0K
Q4 25	$622.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+60.5%	-22.9%
Q2 22	-23.7%	-9.8%
Q3 22	+401.7%	-2.1%
Q4 22	-52.1%	-7.8%
Q1 23	-66.4%	-8.4%
Q2 23	-39.3%	-15.5%
Q3 23	-91.8%	-8.3%
Q4 23	-30.3%	+4.5%
Q1 24	-42.5%	+0.6%
Q2 24	-59.4%	+169.0%
Q3 24	-30.9%	-0.5%
Q4 24	-3.1%	+20.7%
Q1 25	+25.9%	-6.0%
Q2 25	+19.4%	-47.0%
Q3 25	+206.6%	+68.4%
Q4 25	+283.6%	-11.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	64.6%
Q2 22	$2M	79.3%
Q3 22	$2M	12.7%
Q4 22	$2M	125.4%
Q1 23	$3M	169.2%
Q2 23	$2M	123.9%
Q3 23	$2M	167.2%
Q4 23	$2M	184.2%
Q1 24	$3M	242.3%
Q2 24	$2M	273.9%
Q3 24	$2M	216.3%
Q4 24	$3M	240.8%
Q1 25	$3M	199.6%
Q2 25	$2M	191.4%
Q3 25	$4M	150.2%
Q4 25	$2M	47.4%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$12M	—
Q2 22	$12M	$13M
Q3 22	$13M	—
Q4 22	$11M	$12M
Q1 23	$12M	$12M
Q2 23	$12M	$9M
Q3 23	$12M	$9M
Q4 23	$13M	$9M
Q1 24	$14M	$9M
Q2 24	$16M	$10M
Q3 24	$11M	$10M
Q4 24	$12M	$11M
Q1 25	$10M	$12M
Q2 25	$11M	—
Q3 25	$12M	$24M
Q4 25	$7M	$18M

Revenue Segments

Quarter	Exemplar Segment	Operating Segments
Q3 23	$1M	—
Q2 24	$717.0K	—
Q3 24	$953.0K	—
Q2 25	—	$856.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$40M	$72M	$112M
Q2 22	$44M	$71M	$115M
Q3 22	$92M	$62M	$154M
Q4 22	$5M	$51M	$56M
Q1 23	$10M	$94M	$104M
Q2 23	$17M	$72M	$88M
Q3 23	$10M	$64M	$74M
Q4 23	$8M	$55M	$63M
Q1 24	$17M	$27M	$45M
Q2 24	$9M	$10M	$20M
Q3 24	$25M	$4M	$29M
Q4 24	$30M	$68M	$98M
Q1 25	$6M	$74M	$80M
Q2 25	$14M	$46M	$60M
Q3 25	$14M	$107M	$121M
Q4 25	$30M	$68M	$98M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	200M	+0.2%	+3.2%
Q2 22	200M	+0.4%	+0.7%
Q3 22	201M	+0.1%	+0.7%
Q4 22	208M	+3.7%	+4.5%
Q1 23	230M	+10.4%	+15.1%
Q2 23	248M	+7.9%	+23.7%
Q3 23	249M	+0.2%	+23.8%
Q4 23	249M	+0.2%	+19.6%
Q1 24	249M	+0.1%	+8.5%
Q2 24	252M	+1.3%	+1.8%
Q3 24	276M	+9.3%	+11.0%
Q4 24	293M	+6.2%	+17.7%
Q1 25	294M	+0.3%	+17.9%
Q2 25	296M	+0.9%	+17.5%
Q3 25	296M	0.0%	+7.5%
Q4 25	313M	+5.6%	+6.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$28.9K	191
Q2 22	$15.2K	191
Q3 22	$87.5K	191
Q4 22	$53.4K	33
Q1 23	$56.1K	33
Q2 23	$53.5K	33
Q3 23	$41.8K	33
Q4 23	$49.1K	25
Q1 24	$42.6K	25
Q2 24	$28.7K	25
Q3 24	$38.1K	25
Q4 24	$47.6K	25
Q1 25	$53.6K	25
Q2 25	$34.2K	25
Q3 25	$116.9K	25
Q4 25	$23	200K

Revenue / Employee